dc.contributor.author |
Black, DM |
en |
dc.contributor.author |
Delmas, PD |
en |
dc.contributor.author |
Eastell, R |
en |
dc.contributor.author |
Reid, Ian |
en |
dc.contributor.author |
Boonen, S |
en |
dc.contributor.author |
Cauley, JA |
en |
dc.contributor.author |
Cosman, F |
en |
dc.contributor.author |
Lakatos, PL |
en |
dc.contributor.author |
Leung, PC |
en |
dc.contributor.author |
Man, Z |
en |
dc.contributor.author |
Mautalen, CA |
en |
dc.contributor.author |
Mesenbrink, P |
en |
dc.contributor.author |
Hu, H |
en |
dc.contributor.author |
Caminis, J |
en |
dc.contributor.author |
Tong, K |
en |
dc.contributor.author |
Rosario-Jansen, T |
en |
dc.contributor.author |
Krasnow, J |
en |
dc.contributor.author |
Hue, TF |
en |
dc.contributor.author |
Sellmeyer, D |
en |
dc.contributor.author |
Eriksen, EF |
en |
dc.contributor.author |
Cummings, SR |
en |
dc.date.accessioned |
2012-03-21T00:15:36Z |
en |
dc.date.issued |
2007 |
en |
dc.identifier.citation |
New England Journal of Medicine 356(18):1809-1822 2007 |
en |
dc.identifier.issn |
0028-4793 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/14757 |
en |
dc.description.abstract |
Background A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. Methods In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. |
en |
dc.publisher |
Massachusetts Medical Society |
en |
dc.relation.ispartofseries |
New England Journal of Medicine |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Detail obtained from http://www.sherpa.ac.uk/romeo/issn/0028-4793/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1056/NEJMoa067312 |
en |
pubs.issue |
18 |
en |
pubs.begin-page |
1809 |
en |
pubs.volume |
356 |
en |
dc.rights.holder |
Copyright: Massachusetts Medical Society |
en |
dc.identifier.pmid |
17476007 |
en |
pubs.end-page |
1822 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
72941 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
17476007 |
en |